APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 35 people and is led by a management team with strong background in drug development, especially in immuno-oncology.


Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and its first application for marketing authorization is under review.
See projects for the present status of Apeiron's portfolio.

 

  • 36 hits13 October 2017

    APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

    APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth.

     

     Presseaussendung

     Press Release